RNS Number : 7575C
Intelligent Ultrasound Group PLC
22 June 2021
22 June 2021
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company")
Results of Annual General Meeting
Intelligent Ultrasound (AIM: MED), the intelligent ultrasound software and simulation company, is pleased to announce that at the Annual General Meeting held at 11:00am today, all resolutions proposed were duly passed. A summary of the voting results is shown below:
For
Discretion
Against
Withheld
Total Votes Cast
% Voting For*
Resolution 1
166,855,527
-
10,000
-
166,865,527
99.99
Resolution 2
166,855,527
-
10,000
-
166,865,527
99.99
Resolution 3
166,855,527
-
10,000
-
166,865,527
99.99
Resolution 4
166,855,527
-
10,000
-
166,865,527
99.99
Resolution 5
141,450,291
-
25,415,236
-
166,865,527
84.77
Resolution 6
141,450,291
-
25,415,236
-
166,865,527
84.77
Resolution 7
166,855,527
-
10,000
-
166,865,527
99.99
Resolution 8
141,450,291
-
10,000
25,405,236
166,865,527
99.99
Resolution 9
166,855,527
-
10,000
-
166,865,527
99.99
Resolution 10
166,855,527
-
10,000
-
166,865,527
99.99
Resolution 11
141,450,291
-
25,415,236
-
166,865,527
84.77
Resolution 12
166,855,527
-
10,000
-
166,865,527
99.99
Resolution 13
162,393,508
-
4,010,022
461,997
166,403,530
97.59
Resolution 14¹
162,393,508
-
4,472,019
-
166,865,527
97.32
* This column represents the number of votes that were cast for the resolutions as a percentage of the number of votes cast in total for each resolution either in person or by proxy.
¹ Special resolution (75% majority required).
The full text of the resolutions is set out in the Notice of Meeting which is available on the website: www.intelligentultrasoundgroup.com
Enquiries:
Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
Paul McManus
Mob: +44 (0)7980 541 893
About Intelligent Ultrasound Group www.intelligentultrasound.com
Intelligent Ultrasound (AIM: IUG) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market. Based in Cardiff in the UK and Atlanta in the US, the Group operates two divisions:
Clinical AI Division
Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in the market include:
ScanNav Assist
ScanNav Assist uses machine-learning based algorithms to automatically identify and grade ultrasound images. GE Healthcare's SonoLyst software on their Voluson SWIFT ultrasound machine incorporates the ScanNav Assist AI technology and has received 510(k) clearance from the FDA for sale in the USA. SonoLyst is the world's first fully integrated AI tool that recognises the 20 views recommended by the International Society of Ultrasound in Obstetrics and Gynaecology mid-trimester practice guidelines for fetal imaging.
ScanNav Anatomy
ScanNav Anatomy PNB uses machine-learning based algorithms to simplify ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting software for a range of medical procedures. ScanNav Anatomy has received CE approval and has also been submitted for FDA regulatory approval.
ScanNav Anatomy PNB is therefore not available for sale in the US or any other territory requiring government approval for this type of product.
Simulation Division
Focusses on hi-fidelity ultrasound education and training through simulation. Its main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid module and the new AI-based Anatomy PNB training simulator. To date over 1,000 simulators have been sold to over 600 medical institutions around the world.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGSEUFMEEFSESM
